Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans
단계 해당 없음
완료
NCT03077360
| 대상 질환 | Diabetes Mellitus, Type 2, Pre-diabetes, Obesity |
|---|
| 임상 단계 | 단계 해당 없음 |
|---|
| 스폰서 | University of Colorado, Denver |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 62 명 |
|---|
| 중재(약물) | Lifestyle |
|---|
| 시작일 | 2017년 2월 1일 |
|---|
| 완료일 | 2020년 11월 19일 |
|---|
| 결과 공개일 | 2022년 6월 21일 |
|---|
요약
The rationale for the proposed research is that elucidating changes in localized diacylglycerol (DAG) and sphingolipid species that predict insulin sensitivity will reveal specific localized lipids to target in therapeutics for type 2 diabetes. To attain the overall objective, the investigators propose three specific aims: 1. Identify the influence of sarcolemmal DAG and sphingolipids on cell signaling and insulin sensitivity before and after insulin sensitizing lifestyle interventions. Strong preliminary data shape the hypothesis that sarcolemmal 1,2-disaturated DAG and C18:0 ceramide species will decrease after insulin sensitizing lifestyle interventions, leading to less Protein kinase C (PKC) and Protein phosphatase 2A (PP2A) activation, and enhanced insulin signaling. Skeletal muscle DAG and sphingolipid isomers, species, localization, and de novo synthesis will be measured before and after diet-induced weight loss or exercise training interventions in obese men and women. Insulin sensitivity will be measured using insulin clamps, and muscle lipids using Liquid Chromatography Mass Spectrometry (LC/MS). 2. Determine the impact of mitochondrial/ER (endoplasmic reticulum) DAG and
Percent Change in Insulin Sensitivity Compared to Baseline Measurement.
Baseline and 12 weeks · Percent change
| Weight Loss Only | 31.8 ± 8.8 Percent change |
|---|
| Exercise Only | 17.4 ± 8.7 Percent change |
|---|
| Delayed Intervention Control | -4.8 ± 9.3 Percent change |
|---|
Percent Change in Localized Muscle Lipids Compared to Baseline
Baseline and 12 weeks · percentage change
| Weight Loss Only | -25 ± 6 percentage change |
|---|
| Exercise Only | -30 ± 7 percentage change |
|---|
| Delayed Intervention Control | 5 ± 6 percentage change |
|---|
| Weight Loss Only | -20 ± 5 percentage change |
|---|
| Exercise Only | -25 ± 5 percentage change |
|---|
| Delayed Intervention Control | 10 ± 3 percentage change |
|---|
Percent Change in Body Weight Compared to Baseline Measurement
Baseline, 3 Months · Percent Change
| Weight Loss Only | -10.5 ± 0.9 Percent Change |
|---|
| Exercise Only | -0.5 ± 0.5 Percent Change |
|---|
| Delayed Intervention Control | 0.5 ± 0.4 Percent Change |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.